Mirum Pharmaceuticals Inc. stocks have been trading up by 12.26 percent following strong clinical trial results boosting investor optimism.
Click Here for a Millionaire's POV on Trading MIRM
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Brelovitug hit the primary endpoint in Mirum’s Phase 2b AZURE-1 HDV trial, with strong antiviral activity, ALT normalization, and clean safety, setting up Phase 3 data in H2 2026 and a possible 2027 launch.
- An 100% virologic response in the 300 mg weekly arm positions brelovitug as a potential single-agent HDV therapy and a major value driver for MIRM.
- Mirum will host a call on 2026/05/04 to unveil topline VISTAS data for volixibat in PSC, adding another key catalyst on traders’ calendars.
- H.C. Wainwright, Baird, and Stifel all raised price targets on MIRM after the HDV readout, reinforcing the stock’s status as a rare-disease growth story.
- New inducement equity awards and the upcoming Q1 2026 earnings call point to continued build-out and more updates on Mirum’s commercial and late-stage pipeline.
Live Update At 12:32:58 EDT: On Monday, May 04, 2026 Mirum Pharmaceuticals Inc. stock [NASDAQ: MIRM] is trending up by 12.26%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Mirum Pharmaceuticals, trading as MIRM, is acting like a classic momentum biotech with real numbers behind the story. The stock has climbed from the mid-$90s in mid-April to a recent close above $108, with Friday’s range stretching from $88.34 to $110.49. That’s a big intraday expansion in volatility, which day traders love.
On the intraday tape, MIRM showed a strong morning surge from a $89.38 open to near $110 by midday, then consolidated in a tight band around $108–$110. That behavior often signals buyers in control and shorts on the run.
Fundamentally, Mirum posted about $521.3M in revenue over the trailing period, with revenue up roughly 89% over three years. This is not a pre-revenue story. Profitability is still negative, with a pretax margin around -43.6% and negative returns on equity and assets, which is typical for an aggressively growing biotech building out a commercial rare-disease franchise.
More Breaking News
- PN Stock Rockets On Volatility As Traders Target Breakout Levels
- SEALSQ (LAES) Stock Draws Traders After Quantum‑Driven Growth
- MIRM Stock Jumps As HDV Data Sends Analysts Scrambling Higher
- NBIS Stock Jumps As Nebius Lands TD SYNNEX AI Deal
MIRM carries leverage, with total debt-to-equity near 1.0, but liquidity looks solid: a current ratio of 2.7 and nearly $296.7M in cash. Valuation is rich, with price-to-sales over 11 and price-to-book near 18.7, which tells traders the market is already baking in big expectations from the HDV and PSC pipelines.
Why Traders Are Watching MIRM Right Now
MIRM is on every biotech trader’s radar because the clinical story finally caught up to the chart. Mirum Pharmaceuticals reported that its monoclonal antibody brelovitug met the primary endpoint in the Phase 2b AZURE-1 trial in chronic hepatitis delta virus. This is not a small incremental win. The trial showed strong antiviral activity, ALT normalization, and a favorable safety profile, and Phase 3 topline data are now guided for H2 2026 with a possible U.S. BLA filing and launch in 2027.
For traders, the standout detail is the 100% virologic response in the 300 mg weekly arm and strong responses in the 900 mg monthly arm, with good tolerability. That kind of signal positions brelovitug as a potential single-agent HDV therapy. In plain English: one drug, real efficacy, clean enough safety to move forward. That is exactly the kind of setup that can justify MIRM’s premium multiples.
The Street responded fast. H.C. Wainwright lifted its price target on Mirum Pharmaceuticals to $150 from $130 and kept a Buy rating, calling MIRM a top pick off the AZURE-1 data. Baird bumped its target to $112 from $95, highlighting that the HDV results support the value of Mirum’s Bluejay acquisition. Stifel raised its target from $125 to $130 and reiterated its bullish stance. When three separate firms all walk their targets higher on the same data set, traders pay attention.
On top of that, Mirum will host a call on 2026/05/04 to review VISTAS topline data for volixibat in primary sclerosing cholangitis. That’s the next clear catalyst for MIRM, layered on top of the HDV momentum. Between that event and an upcoming Q1 2026 earnings call, traders have multiple dates to trade around.
Conclusion
MIRM is showing the exact mix of ingredients momentum traders look for: a strong uptrend on the chart, a real clinical inflection point, and a calendar packed with upcoming catalysts. Mirum Pharmaceuticals delivered a Phase 2b win in HDV with brelovitug, backed by 100% response in a key dosing arm and a path toward Phase 3 data in 2026 and a potential 2027 U.S. launch. That’s why multiple analysts rushed to raise targets on Mirum Pharmaceuticals and reaffirm the bullish case.
At the same time, MIRM’s financials tell a familiar biotech story. Rapid revenue growth, negative earnings, heavy R&D, and a balance sheet that still relies on capital markets and future commercial success. The company is also adding staff and granting stock options, another sign Mirum is scaling for what it believes is a bigger future.
For active traders, the message is simple: treat MIRM like any volatile biotech runner. Map the key dates — the 2026/05/04 VISTAS call, the Q1 2026 update, and later the Phase 3 AZURE-1/4 readouts — and trade the volatility, not the story you want to believe. That kind of disciplined planning lines up with a core trading mindset. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.”. As Tim Sykes likes to say, “Trade like a sniper, not a machine gun — wait for the best setups, then strike and step aside.” This coverage of MIRM is for educational and research purposes only, but the tape action and news flow make it a name many traders will keep on their screens.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.